Amycretin vs Orforglipron
Novo's Amylin + GLP-1 vs Lilly's Oral GLP-1 (2026)
Amycretin (Novo Nordisk) and orforglipron (Eli Lilly, branded Foundayo) are two of the most important next-wave obesity drugs. Amycretin combines GLP-1 and amylin in both oral and injectable forms and is in Phase 3; orforglipron is an approved oral GLP-1 pill. Here's how they compare.
Amycretin vs Orforglipron: At a Glance
- ✓Single molecule with GLP-1 + amylin activity
- ✓Developed in both oral and injectable forms
- ✓Early data among the highest of any oral candidate
- ✓Advanced to Phase 3 (oral and subcutaneous) in 2026
- ✓Investigational — not yet approved
- ✓Novo Nordisk
- ✓Non-peptide oral GLP-1 receptor agonist
- ✓Once-daily pill — no fasting, any time
- ✓Phase 2 ~14.7%; ATTAIN-1 up to 27.3 lbs
- ✓FDA-approved (Foundayo) April 2026
- ✓Available now
- ✓Eli Lilly
Detailed Comparison
| Feature | Amycretin | Orforglipron (Foundayo) |
|---|---|---|
| Mechanism | GLP-1 + amylin (dual activity) | GLP-1 only (non-peptide)Best |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Formats | Oral + injectable | Oral pill |
| Dosing | Under study | Once daily, with or without food |
| Stage | Phase 3 (2026) | FDA-approved (April 2026) |
| Availability | Not yet available | Available now |
| Weight Loss | High in early trials | Phase 2 ~14.7%; up to 27.3 lbs |
| Brand | None yet | Foundayo |
| Extra Pathway | Amylin satiety signaling | None (single pathway) |
How They Differ
Available Today
Orforglipron (Foundayo) is FDA-approved and shipping. Amycretin is still investigational, so it can't be obtained outside trials.
Two Pathways vs One
Amycretin adds amylin satiety signaling to GLP-1, which may push efficacy higher than a GLP-1-only pill like orforglipron.
Format Flexibility
Amycretin is being developed as both a pill and an injection; orforglipron is oral only. Different options for different patients.
Convenience Now
Orforglipron's key selling point is a no-fasting daily pill you can take today. Amycretin's convenience profile depends on its final format and dose.
Early-Stage Promise
Amycretin's early weight-loss numbers are among the highest reported for an oral-capable candidate — but early and short.
Novo vs Lilly
This is another front in the Novo–Lilly obesity race: Novo's amylin-GLP-1 strategy vs Lilly's small-molecule oral GLP-1.
Which Should You Watch?
If you want an oral obesity drug today, orforglipron — sold as Foundayo — is the one you can actually get. It's an FDA-approved, once-daily, no-fasting pill with solid Phase 2/3 weight-loss data. That availability is a decisive advantage over anything still in trials.
Amycretin is the higher-upside bet. By combining GLP-1 with amylin in a single molecule — and pursuing both oral and injectable versions — it posted some of the strongest early numbers of any next-wave candidate, and it advanced to Phase 3 in 2026. But "Phase 3" means real-world availability is still down the road.
For now: orforglipron if you want a pill now, amycretin to watch for potentially greater efficacy later. Track whatever you take in Shotlee so you have a clean baseline to judge a future switch.
Amycretin vs Orforglipron: Frequently Asked Questions
Orforglipron (Foundayo) is approved and available now as an oral GLP-1 pill. Amycretin (Novo) adds amylin to GLP-1 and posted higher early weight-loss numbers, but it's still in Phase 3 and not available. Orforglipron wins on availability; amycretin has higher potential efficacy.
Amycretin is a Novo Nordisk molecule with both GLP-1 and amylin activity, developed in oral and injectable forms. Orforglipron is Eli Lilly's non-peptide oral GLP-1 pill, branded Foundayo. Amycretin adds a second pathway; orforglipron is GLP-1 only.
No. Amycretin is investigational and advanced to Phase 3 in 2026; it's not available outside clinical trials. Orforglipron (Foundayo) is FDA-approved and available.
Yes. Foundayo is the brand name for orforglipron, Eli Lilly's approved oral GLP-1 pill.
Yes. Shotlee tracks orforglipron (Foundayo) and any GLP-1-class protocol, including investigational ones like amycretin if you're in a trial — dose, weight, and side effects.
Track Foundayo or Any GLP-1 in Shotlee
Free dose logging, weight trends, and side-effect tracking for approved and investigational obesity drugs.